ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

Andrew Chung  |  January 15, 2017

NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the…

Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States

Pfizer  |  January 13, 2017

On Jan. 6, Pfizer Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has included payment information for INFLECTRA (infliximab-dyyb), a biosimilar to REMICADE (infliximab), in its January Average Selling Price (ASP) pricing file. This pricing took effect as of January 1, 2017. Additional claims processing information is listed in the MLN Matters…

Guselkumab Improves Active Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD  |  January 11, 2017

A study showed that guselkumab may decrease symptoms of psoriatic arthritis and improve quality of life in adult patients…

Rituximab Promising for Dermatitis Herpetiformis

Marilynn Larkin  |  January 6, 2017

NEW YORK—Rituximab may be an effective treatment for recalcitrant dermatitis herpetiformis (DH), according to a recent case study. “DH is an autoimmune blistering disease which is commonly associated with celiac disease and can present with debilitating pruritic blisters on extensor surfaces,” explained Dr. Ron Feldman of Emory University School of Medicine. “The most common treatments…

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

New Test Yields Rapid Infliximab Drug Concentrations

Will Boggs, MD  |  December 22, 2016

NEW YORK (Reuters Health)—A new test provides rapid infliximab drug concentrations that enable immediate dosing adjustments, researchers from Belgium report. “With this rapid test, our biggest wish is to persuade physicians to now perform and use infliximab measurements also in their own daily clinical practice, as many practical and organizational issues that went along with…

U.S. Democrats Seek Trump’s Cooperation on Drug Price Reform

Reuters Staff  |  December 22, 2016

NEW YORK (Reuters)—A group of Democratic senators took their plans to tackle rising drug costs to President-Elect Donald Trump on Tuesday, asking him to work with them and Republicans on the issue. In a letter dated Tuesday, the 19 senators named five areas for cooperation: allowing the Medicare program to negotiate prescription prices, increasing transparency,…

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a recent study, patients with psoriatic arthritis taking tofacitinib had a decrease in disease activity compared with placebo…

Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases

Reuters Staff  |  December 16, 2016

NEW YORK (Reuters Health)—Statin treatment is associated with an attenuation of the increases in serum lipids experienced by rheumatoid arthritis patients on tocilizumab, according to a post-hoc analysis of clinical trials. Treatment with the interleukin-6 receptor-alpha inhibitor tocilizumab is known to raise total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels. To explore the possible effect of…

  • « Previous Page
  • 1
  • …
  • 75
  • 76
  • 77
  • 78
  • 79
  • …
  • 125
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences